GlassScriptPhysician profile
Andrea K Willhite
NPI 1801893748
$2,380.46
in general payments reported to CMS, 2019-2025
33 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $502 · 2021: $462 · 2022: $216 · 2023: $295 · 2024: $204 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.91 | 2020-2025 | Vraylar, Mavyret, Ubrelvy |
| Glaxosmithkline, LLC. | $198.12 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Amgen INC. | $170.75 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $168.96 | 2019-2024 | Wegovy |
| Pfizer INC. | $139.25 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $117.95 | 2019-2022 | |
| Corcept Therapeutics | $100.96 | 2023-2025 | Korlym |
| Abbott Laboratories | $86.81 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $79.12 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.77 | 2020-2024 | Jardiance |
| Astellas Pharma US INC | $74.46 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.17 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $65.48 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $61.63 | 2021-2025 | Austedo Xr |
| Allergan, INC. | $51.88 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49.65 | 2020-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $45.50 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.49 | 2019-2021 | |
| Axsome Therapeutics, INC. | $36.98 | 2023-2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $30.23 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $28.23 | 2020 | |
| Merck Sharp & Dohme LLC | $26.94 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.01 | 2021 | |
| Eisai INC. | $21.36 | 2021 | |
| Si-Bone, INC. | $18.45 | 2021 | |
| Seqirus USA INC | $17.78 | 2025 | Fluad, Flucelvax |
| E.R. Squibb & Sons, L.L.C. | $16.81 | 2020 | |
| Amarin Pharma, INC. | $16.45 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.64 | 2021 | |
| Exact Sciences Corporation | $14.28 | 2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $13.84 | 2020 | |
| Genentech USA, INC. | $12.95 | 2022 | |
| Collegium Pharmaceutical, INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Willhite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.